TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI): Pre-, Peri- and Postnatal Programming and Origins of Disease: Early Targeting the Epidemics of Allergy and Overweight
Brief Summary: Combined programme: Nutrition, Allergy, Mucosal immunology and Intestinal microbiota (NAMI) was created with the objective to reverse the rising trend of chronic inflammatory diseases, such as allergic disease and obesity, by control of the internal and external environments of the infant. To approach this problem, the project aims to characterize

* how immunology is regulated during pregnancy and early infancy,
* how the immune interaction between mother and child is influenced by nutritional and microbial factors, and
* how the regulation is related to disease risk.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low glycemic load | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low fat diet | Intervention Type: BEHAVIORAL; Name: Low glycemic load; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low fat diet; Assigned to Arm(s): 2
B: Arm Label: Myo-inositol powder; Type: EXPERIMENTAL; Interventions: Dietary Supplement: inositol + folic acid | Arm Label: Myo-inositol soft gel capsules; Type: EXPERIMENTAL; Interventions: Dietary Supplement: inositol + folic acid | Arm Label: Folic acid; Type: PLACEBO_COMPARATOR; Interventions: Drug: Folic Acid | Intervention Type: DIETARY_SUPPLEMENT; Name: inositol + folic acid; Assigned to Arm(s): Myo-inositol powder | Intervention Type: DIETARY_SUPPLEMENT; Name: inositol + folic acid; Assigned to Arm(s): Myo-inositol soft gel capsules | Intervention Type: DRUG; Name: Folic Acid; Assigned to Arm(s): Folic acid
C: Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Probiotics + Dietary counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and probiotics | Arm Label: Dietary counseling + placebo; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and placebo | Arm Label: Prebiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo capsules | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary counselling and placebo; Assigned to Arm(s): Dietary counseling + placebo | Intervention Type: BEHAVIORAL; Name: Dietary counselling and probiotics; Assigned to Arm(s): Probiotics + Dietary counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo capsules; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotics; Assigned to Arm(s): Prebiotics
D: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle | Intervention Type: BEHAVIORAL; Name: Lifestyle; Assigned to Arm(s): Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI): Pre-, Peri- and Postnatal Programming and Origins of Disease: Early Targeting the Epidemics of Allergy and Overweight
Brief Summary: Combined programme: Nutrition, Allergy, Mucosal immunology and Intestinal microbiota (NAMI) was created with the objective to reverse the rising trend of chronic inflammatory diseases, such as allergic disease and obesity, by control of the internal and external environments of the infant. To approach this problem, the project aims to characterize

* how immunology is regulated during pregnancy and early infancy,
* how the immune interaction between mother and child is influenced by nutritional and microbial factors, and
* how the regulation is related to disease risk.


Options:
A: Arm Label: exercise; Type: EXPERIMENTAL; Interventions: Behavioral: specific training program | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: standard | Intervention Type: OTHER; Name: standard; Assigned to Arm(s): control | Intervention Type: BEHAVIORAL; Name: specific training program; Assigned to Arm(s): exercise
B: Arm Label: Marinol; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Marinol D-40 | Arm Label: Nutrition counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Marinol D-40; Assigned to Arm(s): Marinol
C: Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Probiotics + Dietary counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and probiotics | Arm Label: Dietary counseling + placebo; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and placebo | Arm Label: Prebiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo capsules | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary counselling and placebo; Assigned to Arm(s): Dietary counseling + placebo | Intervention Type: BEHAVIORAL; Name: Dietary counselling and probiotics; Assigned to Arm(s): Probiotics + Dietary counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo capsules; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotics; Assigned to Arm(s): Prebiotics
D: Arm Label: Exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise training

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI): Pre-, Peri- and Postnatal Programming and Origins of Disease: Early Targeting the Epidemics of Allergy and Overweight
Brief Summary: Combined programme: Nutrition, Allergy, Mucosal immunology and Intestinal microbiota (NAMI) was created with the objective to reverse the rising trend of chronic inflammatory diseases, such as allergic disease and obesity, by control of the internal and external environments of the infant. To approach this problem, the project aims to characterize

* how immunology is regulated during pregnancy and early infancy,
* how the immune interaction between mother and child is influenced by nutritional and microbial factors, and
* how the regulation is related to disease risk.


Options:
A: Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Probiotics + Dietary counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and probiotics | Arm Label: Dietary counseling + placebo; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and placebo | Arm Label: Prebiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo capsules | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary counselling and placebo; Assigned to Arm(s): Dietary counseling + placebo | Intervention Type: BEHAVIORAL; Name: Dietary counselling and probiotics; Assigned to Arm(s): Probiotics + Dietary counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo capsules; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotics; Assigned to Arm(s): Prebiotics
B: Arm Label: Intensive Counseling Group; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary and lifestyle counseling | Arm Label: Routine care group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary and lifestyle counseling; Assigned to Arm(s): Intensive Counseling Group
C: Arm Label: Lifestyle, follow-up, early care, standard care high/low risk; Type: OTHER; Interventions: Behavioral: Lifestyle: diet and exercise | Arm Label: Close follow-up; Type: OTHER; Interventions: Behavioral: Close follow-up: reporting diaries of food and exercise | Intervention Type: BEHAVIORAL; Name: Lifestyle: diet and exercise; Assigned to Arm(s): Lifestyle, follow-up, early care, standard care high/low risk | Intervention Type: BEHAVIORAL; Name: Close follow-up: reporting diaries of food and exercise; Assigned to Arm(s): Close follow-up
D: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle | Intervention Type: BEHAVIORAL; Name: Lifestyle; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Longitudinal Study Assessing the Infectious Status and Immunity of Mothers and Their Children in Lambaréné, Including Intermittent Treatment of Children With Sulfadoxine-pyrimethamine for Malaria Control and Its Impact on Long-term Health
Brief Summary: The general goal of the project is to assess the infectious status and immunity of mothers and children living in a malaria region. A major part of the study involves administering an effective antimalarial, sulfadoxine-pyrimethamine (Fansidar®), to children at the same timepoints as vaccinations, i.e. at age 3, 9 and 15 months. The main objective is to study safety, efficacy, and consequences of such a strategy in particular the ability to reduce the risk of anemia.


Options:
A: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sulphadoxine-pyrimethamine; Type: EXPERIMENTAL; Interventions: Drug: sulphadoxine-pyrimethamine, Drug: Sulphadoxine-pryrimethamine | Arm Label: Mefloquine; Type: EXPERIMENTAL; Interventions: Drug: mefloquine, Drug: IPTi mefloquine | Arm Label: Chlorproguanil dapsone; Type: EXPERIMENTAL; Interventions: Drug: Chlorproguanil-dapsone, Drug: Chlorproguanil dapsone | Intervention Type: DRUG; Name: sulphadoxine-pyrimethamine; Assigned to Arm(s): Sulphadoxine-pyrimethamine | Intervention Type: DRUG; Name: mefloquine; Assigned to Arm(s): Mefloquine | Intervention Type: DRUG; Name: Chlorproguanil-dapsone; Assigned to Arm(s): Chlorproguanil dapsone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sulphadoxine-pryrimethamine; Assigned to Arm(s): Sulphadoxine-pyrimethamine | Intervention Type: DRUG; Name: IPTi mefloquine; Assigned to Arm(s): Mefloquine | Intervention Type: DRUG; Name: Chlorproguanil dapsone; Assigned to Arm(s): Chlorproguanil dapsone
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Seasonal IPT in children - Sulfadoxine-pyrimethamine | Intervention Type: DRUG; Name: Seasonal IPT in children - Sulfadoxine-pyrimethamine; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Sulfadoxine-pyrimethamine used for IPTi, Drug: IPTi | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine used for IPTi; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: IPTi; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Longitudinal Study Assessing the Infectious Status and Immunity of Mothers and Their Children in Lambaréné, Including Intermittent Treatment of Children With Sulfadoxine-pyrimethamine for Malaria Control and Its Impact on Long-term Health
Brief Summary: The general goal of the project is to assess the infectious status and immunity of mothers and children living in a malaria region. A major part of the study involves administering an effective antimalarial, sulfadoxine-pyrimethamine (Fansidar®), to children at the same timepoints as vaccinations, i.e. at age 3, 9 and 15 months. The main objective is to study safety, efficacy, and consequences of such a strategy in particular the ability to reduce the risk of anemia.


Options:
A: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Intermittent preventive treatment with AQ+ SP | Intervention Type: DRUG; Name: Intermittent preventive treatment with AQ+ SP; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Intrarectal quinine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Longitudinal Study Assessing the Infectious Status and Immunity of Mothers and Their Children in Lambaréné, Including Intermittent Treatment of Children With Sulfadoxine-pyrimethamine for Malaria Control and Its Impact on Long-term Health
Brief Summary: The general goal of the project is to assess the infectious status and immunity of mothers and children living in a malaria region. A major part of the study involves administering an effective antimalarial, sulfadoxine-pyrimethamine (Fansidar®), to children at the same timepoints as vaccinations, i.e. at age 3, 9 and 15 months. The main objective is to study safety, efficacy, and consequences of such a strategy in particular the ability to reduce the risk of anemia.


Options:
A: Arm Label: SP and amodiaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: SP plus amodiaquine | Arm Label: SP placebo plus amodiaquine placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: SP placebo plus amodiaquine placebo | Intervention Type: DRUG; Name: SP plus amodiaquine; Assigned to Arm(s): SP and amodiaquine | Intervention Type: DRUG; Name: SP placebo plus amodiaquine placebo; Assigned to Arm(s): SP placebo plus amodiaquine placebo
B: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo | Intervention Type: DRUG; Name: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo; Assigned to Arm(s): 1, 2, 3
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sulphadoxine-pyrimethamine; Type: EXPERIMENTAL; Interventions: Drug: sulphadoxine-pyrimethamine, Drug: Sulphadoxine-pryrimethamine | Arm Label: Mefloquine; Type: EXPERIMENTAL; Interventions: Drug: mefloquine, Drug: IPTi mefloquine | Arm Label: Chlorproguanil dapsone; Type: EXPERIMENTAL; Interventions: Drug: Chlorproguanil-dapsone, Drug: Chlorproguanil dapsone | Intervention Type: DRUG; Name: sulphadoxine-pyrimethamine; Assigned to Arm(s): Sulphadoxine-pyrimethamine | Intervention Type: DRUG; Name: mefloquine; Assigned to Arm(s): Mefloquine | Intervention Type: DRUG; Name: Chlorproguanil-dapsone; Assigned to Arm(s): Chlorproguanil dapsone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sulphadoxine-pryrimethamine; Assigned to Arm(s): Sulphadoxine-pyrimethamine | Intervention Type: DRUG; Name: IPTi mefloquine; Assigned to Arm(s): Mefloquine | Intervention Type: DRUG; Name: Chlorproguanil dapsone; Assigned to Arm(s): Chlorproguanil dapsone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Longitudinal Study Assessing the Infectious Status and Immunity of Mothers and Their Children in Lambaréné, Including Intermittent Treatment of Children With Sulfadoxine-pyrimethamine for Malaria Control and Its Impact on Long-term Health
Brief Summary: The general goal of the project is to assess the infectious status and immunity of mothers and children living in a malaria region. A major part of the study involves administering an effective antimalarial, sulfadoxine-pyrimethamine (Fansidar®), to children at the same timepoints as vaccinations, i.e. at age 3, 9 and 15 months. The main objective is to study safety, efficacy, and consequences of such a strategy in particular the ability to reduce the risk of anemia.


Options:
A: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SP, amodiaquine, piperaquine, dihdroartemisinin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: intermittent preventive treatment | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Du-Cotecxin | Intervention Type: DRUG; Name: SP, amodiaquine, piperaquine, dihdroartemisinin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: intermittent preventive treatment; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Du-Cotecxin; Assigned to Arm(s): 3
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulfalene-pyrimethamine plus amodiaquine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin plus piperaquine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulfadoxine pyrimethamine plus piperaquine | Intervention Type: DRUG; Name: sulfalene-pyrimethamine plus amodiaquine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: dihydroartemisinin plus piperaquine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: sulfadoxine pyrimethamine plus piperaquine; Assigned to Arm(s): 3
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Intermittent preventive treatment (SP and amodiaquine) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Intermittent preventive treatment (SP and amodiaquine); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Pivotal Trial to Evaluate the Safety and Efficacy of Nitrogen Mustard (NM) 0.02% Ointment Formulations in Patients With Stage I or IIA Mycosis Fungoides (MF)
Brief Summary: This study will evaluate the efficacy, tolerability and safety of the topical application of mechlorethamine (MCH) formulations in patients with stage I or IIA mycosis fungoides (MF).


Options:
A: Arm Label: 1 (PG - NM (MCH) 0.02%); Type: ACTIVE_COMPARATOR; Interventions: Drug: mechlorethamine-MCH (nitrogen mustard) | Arm Label: 2 (AP - MCH(NM) 0.02%); Type: ACTIVE_COMPARATOR; Interventions: Drug: mechlorethamine-MCH (nitrogen mustard) | Intervention Type: DRUG; Name: mechlorethamine-MCH (nitrogen mustard); Assigned to Arm(s): 1 (PG - NM (MCH) 0.02%), 2 (AP - MCH(NM) 0.02%)
B: Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): N/A
C: Arm Label: KW-0761; Type: EXPERIMENTAL; Interventions: Biological: KW-0761 | Arm Label: Vorinostat; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vorinostat | Intervention Type: BIOLOGICAL; Name: KW-0761; Assigned to Arm(s): KW-0761 | Intervention Type: DRUG; Name: Vorinostat; Assigned to Arm(s): Vorinostat
D: Arm Label: Caelyx; Type: EXPERIMENTAL; Interventions: Drug: pegylated liposomal doxorubicin hydrochloride | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin hydrochloride; Assigned to Arm(s): Caelyx

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pulmonary Rehabilitation in Interstitial Lung Disease - a Multi-Centre, Single-Blinded Randomised Controlled Trial
Brief Summary: Interstitial lung disease (ILD) is a highly disabling group of conditions including idiopathic pulmonary fibrosis (IPF), acute and chronic interstitial pneumonias, connective tissue diseases and sarcoidosis. People with ILD frequently experience breathlessness on exertion, which limits their ability to undertake daily activities. People with ILD report very poor quality of life due to low levels of physical functioning and vitality, and high levels of breathlessness and fatigue. There are few treatments for ILD and those that are available have limited impact on quality of life.

The aim of this study is to assess the effects of Pulmonary Rehabilitation, which consists of specialised exercise training for people with lung disease, on exercise capacity and quality of life in people with ILD. We hypothesis that exercise training will result in reduced dyspnoea, improved exercise tolerance and enhanced quality of life.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: pulmonary rehabilitation | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: pulmonary rehabilitation; Assigned to Arm(s): Arm 1
B: Intervention Type: BEHAVIORAL; Name: Pulmonary Rehabilitation; Assigned to Arm(s): N/A
C: Arm Label: Pulmonary rehabilitation; Type: EXPERIMENTAL; Interventions: Other: Pulmonary rehabilitation program | Arm Label: Controls; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pulmonary rehabilitation program; Assigned to Arm(s): Pulmonary rehabilitation
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: BIBF 1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): BIBF 1120

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of diabetic macular edema.


Options:
A: Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A
B: Arm Label: AVASTIN; Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: OZURDEX; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): AVASTIN | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): OZURDEX
C: Arm Label: Dexamethasone 700 μg; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Dexamethasone 350 μg; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Other: Sham | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone 350 μg, Dexamethasone 700 μg | Intervention Type: OTHER; Name: Sham; Assigned to Arm(s): Sham
D: Arm Label: Dexamethasone 700 μg; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Dexamethasone 350 μg; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Other: Sham | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone 350 μg, Dexamethasone 700 μg | Intervention Type: OTHER; Name: Sham; Assigned to Arm(s): Sham

Answer: D